ArticleThe Journal of biological chemistry2012
Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene.
Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 60 citations in OpenAlex.
- Glycomic Signatures of Plasma IgG Improve Preoperative Prediction of the Invasiveness of Small Lung Nodules.Molecules (Basel, Switzerland) · 2019Trial
- Platelet-localized ST6Gal1 does not impact IgG sialylation.Glycobiology · 2023Article
- Control of lupus activity during pregnancy via the engagement of IgG sialylation: novel crosstalk between IgG sialylation and pDC functions.Frontiers of medicine · 2023Article
- A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.Journal of ovarian research · 2023Article
- Reply to Werner and Nimmerjahn letter to the Glyco-Forum.Glycobiology · 2022Article
- ST6Gal1 in plasma is dispensable for IgG sialylation.Glycobiology · 2022Article
- Article
- Bacterial colonization and TH17 immunity are shaped by intestinal sialylation in neonatal mice.Glycobiology · 2022Article
- Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav-Related Liver Injury.Frontiers in pharmacology · 2022Article
- Immunoglobulin G Glycosylation Changes in Aging and Other Inflammatory Conditions.Experientia supplementum (2012) · 2021Article
- Modulation of hepatocyte sialylation drives spontaneous fatty liver disease and inflammation.Glycobiology · 2020Article
- The history of IgG glycosylation and where we are now.Glycobiology · 2020Review
- Abberant Immunoglobulin G Glycosylation in Rheumatoid Arthritis by LTQ-ESI-MS.International journal of molecular sciences · 2020Article
- Article
- Blood-Borne ST6GAL1 Regulates Immunoglobulin Production in B Cells.Frontiers in immunology · 2020Article
- B cells suppress medullary granulopoiesis by an extracellular glycosylation-dependent mechanism.eLife · 2019Article
- IgG Fc Glycosylation in Human Immunity.Current topics in microbiology and immunology · 2019Review
- IgG and leukocytes: Targets of immunomodulatory α2,6 sialic acids.Cellular immunology · 2018Review
- Emerging glycobiology tools: A renaissance in accessibility.Cellular immunology · 2018Review
- The Glycoscience of Immunity.Trends in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The anti-inflammatory properties associated with intravenous immunoglobulin therapy require the sialic acid modification of the N-glycan of the Fc domain of IgG. Sialylation of the Fc fragment is mediated by β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1), acting on the Gal(β4)GlcNAc terminal structure of the biantennary N-glycans on the Fc domain. However, little is known regarding the in vivo regulation of Fc sialylation and its role in the progression of inflammatory processes. Here, we report that decreased Fc sialylation of circulatory IgG accompanies the acute phase response elicited by turpentine exposure or upon acute exposure to either nontypeable Haemophilus influenzae or ovalbumin. However, Fc sialylation was increased 3-fold from the base line upon transition to chronic inflammation by repeated exposure to challenge. The P1 promoter of the ST6Gal-1 gene is critical for Fc sialylation, but P1 does not drive ST6Gal-1 expression in B cells. The Siat1ΔP1 mouse, with a dysfunctional P1 promoter, was unable to produce sialylated Fc in the systemic circulation, despite the presence of Gal(β4)GlcNAc termini on the Fc glycans. The major contribution of P1 action is to synthesize ST6Gal-1 enzymes that are deposited into the systemic circulation. The data strongly indicate that this pool of extracellular ST6Gal-1 in the blood impacts the sialylation of IgG Fc and that defective Fc sialylation is likely a major contributing mechanism for the proinflammatory tendencies previously noted in Siat1ΔP1 animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.